scholarly journals Antineoplastic agents associated with the development of drug-induced pancreatitis

2021 ◽  
pp. 114-121
Author(s):  
N. A. Arablinskiy ◽  
O. D. Ostroumova ◽  
A. V. Filippova
Keyword(s):  
World Health Organization ◽  
Kinase Inhibitors ◽  
Kinase Inhibitor ◽  
Phase 1 ◽  
Risk Groups ◽  
World Health ◽  
Antitumor Drugs ◽  
Social Significance ◽  
Drug Induced ◽  
Health Organization

The frequency of drug-induced pancreatitis (LIP) is from 2 to 5% of all cases of acute pancreatitis (OP), but it is much more common in risk groups – among children and HIV-infected patients. The use of a number of drugs (drugs) is associated with the development of lipids, among them a special place is occupied by antitumor drugs due to the great medical and social significance of oncological diseases and the appearance in recent years of a large number of new antitumor drugs. The purpose of this review was to review the literature data on antitumor drugs, the use of which is associated with the development of lipids. LI OP developed in 1.8% of patients treated with nivolumab or pembroluzumab. In total, in 14 phase 1-3 studies on the efficacy and safety of ipilimumab, the development of OP was reported in less than 1% of the subjects. Therapy with molecular-targeted targeted drugs, such as tyrosine kinase inhibitors (TKI) or other representatives of the kinase inhibitor class, is also associated with the development of OP. The HP database of the World Health Organization (WHO, World Health Organization Adverse Drug Reaction database) contains reports of individual clinical cases of OP development during treatment with proteosome inhibitors and antibody-drug conjugates. It is known that the following antitumor drugs are also associated with the development of pancreatitis: 6-mercaptopurine, L-asparaginase, tamoxifen, cisplatin, cytarabine, ifosfamide, paclitaxel, docetaxel, oxaliplatin, capecitabine, periwinkle alkaloids, cytosine, cisplatin, interferon alpha-2b, doxorubicin, tamoxifen, gefitinib, vinorelbine, levamizole, methotrexate, 5-fluorouracil, capecitabine, trans-retinoic acid.

scholarly journals BCR-ABL1–like B-Acute Lymphoblastic Leukemia/Lymphoma: A Comprehensive Review

2019 ◽  
Vol 144 (2) ◽  
pp. 150-155 ◽  
Author(s):  
Sarika Jain ◽  
Anu Abraham
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
World Health Organization ◽  
Kinase Inhibitors ◽  
Lymphoblastic Leukemia ◽  
World Health ◽  
Comprehensive Review ◽  
The World ◽  
Health Organization ◽  
Stimulating Factor

Context.— In the 2016 update of the World Health Organization (WHO) classification of hematopoietic neoplasms, BCR-ABL1–like B-acute lymphoblastic leukemia/lymphoma (B-ALL) is added as a new provisional entity that lacks the BCR-ABL1 translocation but shows a pattern of gene expression very similar to that seen in B-ALL with BCR-ABL1. Objective.— To review the kinase-activating alterations and the diagnostic approach for BCR-ABL1–like B-ALL. Data Sources.— We provide a comprehensive review of BCR-ABL1–like B-ALL based on recent literature and the 2016 update of the World Health Organization classification of hematopoietic neoplasms. Conclusions.— Several types of kinase-activating alterations (fusions or mutations) are identified in BCR-ABL1–like B-ALL. The main categories are alterations in the ABL class family of genes, encompassing ABL1, ABL2, PDGFRB, PDGFRA (rare), and colony-stimulating factor 1 receptor (CSF1R) fusions, or the JAK2 class family of genes, encompassing alterations in JAK2, CRLF2, EPOR, and other genes in this pathway. These alterations determine the sensitivity to tyrosine kinase inhibitors. As a wide variety of genomic alterations are included in this category, the diagnosis of BCR-ABL1–like B-ALL is extremely complex. Stepwise algorithms and comprehensive unbiased testing are the 2 ways to approach the diagnosis of BCR-ABL1–like B-ALL.

Drugs associated with drug-induced pancreatitis: focus on rarely discussed drugs

2021 ◽  
Vol 1 (29) ◽  
pp. 33-39
Author(s):  
A. V. Filippova ◽  
E. E. Pavleeva ◽  
O. D. Ostroumova
Keyword(s):  
Central Nervous System ◽  
Acute Pancreatitis ◽  
Acute Inflammation ◽  
World Health ◽  
Antitumor Drugs ◽  
Drug Induced ◽  
The World ◽  
The Central Nervous System ◽  
Inflammatory Drugs ◽  
Health Organization

More than 500 medicines are included in the database of the World Health Organization as drugs that can cause acute inflammation of the pancreas. Drug-induced acute pancreatitis develops against the background of taking many medications (statins, antitumor drugs, drugs for the treatment of diseases of the gastrointestinal tract, analgesics and anti-inflammatory drugs, antimicrobial, antiparasitic and antiviral drugs, drugs for the treatment of tuberculosis, diseases of the central nervous system, estrogens, calcium preparations, etc.) from different classes, while the clinical picture does not differ from pancreatitis of other etiology. Based on this, it is worth paying attention to the reasons that contributed to the development of this pathology. Therefore, one of the main principles of the diagnosis of drug-induced pancreatitis is a thorough collection of a pharmacological history. If you suspect that pancreatitis was caused by a drug, you should immediately stop using it and start traditional therapeutic treatment.

scholarly journals Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase

2019 ◽  
Vol 143 (1) ◽  
pp. 433-436 ◽  
Author(s):  
Philippe Mertz ◽  
Bénédicte Lebrun-Vignes ◽  
Joe-Elie Salem ◽  
Laurent Arnaud
Keyword(s):  
World Health Organization ◽  
World Health ◽  
Capillary Leak ◽  
Drug Induced ◽  
The World ◽  
Health Organization

scholarly journals National routine adult immunisation programmes among World Health Organization Member States: an assessment of health systems to deploy COVID-19 vaccines

2021 ◽  
Vol 26 (17) ◽  
Author(s):  
Sarah R Williams ◽  
Amanda J Driscoll ◽  
Hanna M LeBuhn ◽  
Wilbur H Chen ◽  
Kathleen M Neuzil ◽  
...  
Keyword(s):  
Hepatitis B ◽  
World Health Organization ◽  
Immunisation Programme ◽  
Risk Groups ◽  
Influenza Vaccines ◽  
World Health ◽  
Vaccine Response ◽  
Member States ◽  
Middle Income ◽  
Health Organization

Introduction As SARS-CoV-2 disproportionately affects adults, the COVID-19 pandemic vaccine response will rely on adult immunisation infrastructures. Aim To assess adult immunisation programmes in World Health Organization (WHO) Member States. Methods We evaluated country reports from 2018 on adult immunisation programmes sent to WHO and UNICEF. We described existing programmes and used multivariable regression to identify independent factors associated with having them. Results Of 194 WHO Member States, 120 (62%) reported having at least one adult immunisation programme. The Americas and Europe had the highest proportions of adult immunisation programmes, most commonly for hepatitis B and influenza vaccines (> 47% and > 91% of countries, respectively), while Africa and South-East Asia had the lowest proportions, with < 11% of countries reporting adult immunisation programmes for hepatitis B or influenza vaccines, and none for pneumococcal vaccines. In bivariate analyses, high or upper-middle country income, introduction of new or underused vaccines, having achieved paediatric immunisation coverage goals and meeting National Immunisation Technical Advisory Groups basic functional indicators were significantly associated (p < 0.001) with having an adult immunisation programme. In multivariable analyses, the most strongly associated factor was country income, with high- or upper-middle-income countries significantly more likely to report having an adult immunisation programme (adjusted odds ratio: 19.3; 95% confidence interval: 6.5–57.7). Discussion Worldwide, 38% of countries lack adult immunisation programmes. COVID-19 vaccine deployment will require national systems for vaccine storage and handling, delivery and waste management to target adult risk groups. There is a need to strengthen immunisation systems to reach adults with COVID-19 vaccines.

Sign in / Sign up

Export Citation Format

Share Document